RANDOMIZED EVALUATION OF VAD INTERVENTION BEFORE INOTROPIC THERAPY
Brief Description Of Study
REVIVE-IT is a two-part study consisting of a trial and a registry. The REVIVE-IT Trial is a prospective, randomized, open-label, multicenter trial, evaluating the HeartMate II® LVAS versus a control group consisting of optimal medical management (OMM) in selected non-inotrope dependent, ambulatory, moderately advanced heart failure patients who are not candidates for heart transplantation based upon assessment of comorbidities and age. Patients are randomized to HeartMate II® LVAS or OMM in a 1:1 ratio.